- Conditions
- Alzheimer Disease, Agitation
- Interventions
- KarXT, KarX-EC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
- Conditions
- Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
- Interventions
- Cobenfy KarXT pill (50/20 mg), Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more
- Conditions
- Schizophrenia
- Interventions
- xanomeline-trospium chloride, Oral antipsychotics
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Suwanee, Georgia
- Conditions
- Healthy Volunteers
- Interventions
- KarXT, Midazolam, Fexofenadine, Digoxin
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Bipolar Disorder Type I With Mania
- Interventions
- KarXT, Lithium, Valproate, Lamotrigine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 61
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more
- Conditions
- Schizophrenia, Schizophrenia; Psychosis
- Interventions
- Xanomeline and Trospium Chloride Capsules, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Bellflower, California • Culver City, California + 19 more
- Conditions
- Alzheimer Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Anaheim, California • Fresno, California + 33 more
- Conditions
- Psychiatric Disorders
- Interventions
- KarXT, KarX-EC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Orange, California • Decatur, Georgia + 1 more
- Conditions
- Bipolar-I Disorder With Mania or Mania With Mixed Features
- Interventions
- KarXT, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 23
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and trospium chloride (KarXT)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Bryant, Arkansas • Anaheim, California • Chino, California + 44 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 147
- States / cities
- Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more
- Conditions
- Schizophrenia
- Interventions
- KarXT (xanomeline and trospium)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois